Compare TEX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | SYRE |
|---|---|---|
| Founded | 1933 | 2013 |
| Country | United States | United States |
| Employees | 10700 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.5B |
| IPO Year | 1994 | 2015 |
| Metric | TEX | SYRE |
|---|---|---|
| Price | $64.53 | $102.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $68.80 | ★ $85.08 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,421,000,000.00 | N/A |
| Revenue This Year | $47.67 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $41.70 | $14.51 |
| 52 Week High | $74.69 | $105.09 |
| Indicator | TEX | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 61.66 |
| Support Level | $58.54 | $66.78 |
| Resistance Level | $66.33 | $103.58 |
| Average True Range (ATR) | 3.05 | 6.10 |
| MACD | -0.68 | 0.09 |
| Stochastic Oscillator | 18.36 | 88.51 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.